Welcome to our dedicated page for Calidi Biotherapeutics SEC filings (Ticker: CLDWW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Calidi Biotherapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Calidi Biotherapeutics's regulatory disclosures and financial reporting.
Calidi Biotherapeutics, Inc. (CLDI) reported that director George Peoples received a grant of 4,000 non-qualified stock options on August 17, 2026. These options have an exercise price of $1.36 per share, expire on August 17, 2036, and vest in 1/12 monthly over one year under Calidi’s 2023 Equity Incentive Plan and non-employee director compensation policy. The reported post-transaction derivative holdings of 4,000 options relate only to this grant and do not include options previously granted.
Calidi Biotherapeutics, Inc. (CLDI) reported that director Scott Leftwich received a grant of non-qualified stock options covering 4,000 shares of common stock on August 17, 2026. The options have an exercise price of $1.36 per share, vest in 1/12th monthly over one year starting on the grant date, and expire on August 17, 2036. Following this grant, the filing shows 4,000 options held from this award, excluding any options previously granted.
Calidi Biotherapeutics, Inc. (CLDI) reported that director Alan R. Stewart received a grant of non-qualified stock options for 4,000 shares of common stock. The options have an exercise price of $1.36 per share, expire on August 17, 2036, and were issued under the company’s 2023 Equity Incentive Plan pursuant to its non-employee director compensation policy.
The options vest and become exercisable in 1/12th per month over one year starting on the August 17, 2026 grant date. Following this grant, the reported derivative holdings from this award total 4,000 options, excluding any options previously granted to the director.
Calidi Biotherapeutics, Inc. (CLDI) reported that its Chief Financial Officer, Jackson Andrew C., received a grant of 14,000 incentive stock options to purchase common stock. The options have an exercise price of $1.36 per share, equal to the closing price on August 17, 2026, and expire on August 17, 2036. Under the company’s 2023 Equity Incentive Plan, 25% of the options vest on the one-year anniversary of August 17, 2026, with the remaining 75% vesting in 36 equal monthly installments, subject to continued service. This grant does not include any incentive stock options previously awarded to the officer.
Calidi Biotherapeutics, Inc. (CLDI) reported that director James A. Schoeneck received a grant of 5,000 non-qualified stock options on August 17, 2026. The options have an exercise price of $1.36 per share, vest in 1/12th monthly over one year, expire on August 17, 2036, and were issued under Calidi’s 2023 Equity Incentive Plan pursuant to its non-employee director compensation policy. Following this grant, Schoeneck holds 5,000 options reported here, which do not include options previously granted.
Calidi Biotherapeutics, Inc. (CLDI) reported that its Chief Executive Officer, Eric E. Poma, received a grant of 32,000 incentive stock options under the company’s 2023 Equity Incentive Plan. The options have a $1.36 exercise price, vest over four years based on continued service, and expire on August 17, 2036. This grant does not include any options previously awarded to him.
Calidi Biotherapeutics, Inc. (CLDI) reported that Chief Scientific Officer Antonio Fernandez Santidrian received a grant of 16,000 incentive stock options under the company’s 2023 Equity Incentive Plan. The options have an exercise price of $1.36 per share and expire on August 17, 2036.
According to the vesting schedule, 25% of the options vest on the one-year anniversary of August 17, 2026, and the remaining 75% vest in equal monthly installments over 36 months, subject to continued service. The filing notes this grant does not include incentive stock options previously granted to the reporting person.
Calidi Biotherapeutics, Inc. (CLDI) reported that director Sanders Corazon (Corsee) D. received a grant of non-qualified stock options on August 17, 2026. The grant covers 6,000 options to purchase common stock at an exercise price of $1.36 per share, equal to the closing price on the grant date. These options vest and become exercisable in 1/12th monthly installments over one year, starting on the grant date, and expire on August 17, 2036. The options were granted under Calidi’s non-employee director compensation policy and issued pursuant to its 2023 Equity Incentive Plan. The reported post-transaction holding of 6,000 options reflects only this grant and does not include options previously granted to the director.
Calidi Biotherapeutics, Inc. has an institutional holder, Armistice Capital, LLC, reporting beneficial ownership of 63,391 shares of common stock as of June 30, 2026. This represents 4.99% of the outstanding common stock.
Armistice Capital is investment manager to Armistice Capital Master Fund Ltd., which directly holds the shares. Steven Boyd, as managing member of Armistice Capital, may be deemed to share voting and investment power over these shares. The filer notes ownership of 5 percent or less of the class.
Calidi Biotherapeutics, Inc. reported a continued operating loss while restructuring its capital base for the quarter ended June 30, 2026. A 1-for-16 reverse stock split effective July 30, 2026 reduced outstanding common shares from 33,471,951 to approximately 2,092,023, with trading on a split-adjusted basis beginning July 31, 2026.
Total assets were $7.2 million, including cash of $4.1 million and restricted cash of $0.2 million. Total liabilities were $4.1 million, leaving total equity of $3.1 million. The company carries a $0.6 million promissory note at a 15% interest rate and warrant liabilities of $68 thousand.
For the three and six months ended June 30, 2026, net losses were $4.2 million and $8.3 million, respectively, compared with $5.8 million and $10.8 million in the prior-year periods, reflecting lower operating expenses. Net cash used in operating activities for the first half of 2026 was $8.5 million, versus $12.0 million a year earlier. The accumulated deficit reached $149.9 million.
Management states there is substantial doubt about the company’s ability to continue as a going concern within 12 months, given recurring losses, negative cash flows, and limited cash resources. To fund operations, Calidi recently raised capital through offerings including a March 2026 confidentially marketed public offering and at-the-market sales, and it expects to seek additional equity or debt financing.